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HER = human epidermal growth factor receptor; mTOR = mammalian target of rapamycin; P-Akt = phosphorylated Akt; PDK = phosphoinositide-
dependent protein kinase; PI3K = phosphatidylinositol 3′-kinase; S6K = P70 S6 protein kinase.
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Abstract
Recent studies indicate that constitutive signaling through the
phosphatidylinositol 3′-kinase (PI3K) pathway is a cause of
treatment resistance in breast cancer patients. This implies that
patients with tumors that exhibit aberrant PI3K signaling may
benefit from targeted pathway inhibitors. The first agents to make it
to the clinic are the rapamycin analogs. These compounds inhibit
the downstream PI3K effector mTOR (mammalian target of
rapamycin). A study presented in this issue of Breast Cancer
Research suggests that recently developed inhibitors of
phosphoinositide-dependent protein kinase 1, a more proximal
target of the PI3K pathway, may provide an alternative route to
effective PI3K pathway inhibition for breast cancer treatment.
Introduction
The phosphatidylinositol 3′-kinase (PI3K) signaling cascade
is involved in regulating many cellular processes that are
required for tumorigenesis, including protein synthesis and
glucose metabolism, cell survival, proliferation, cell migration,
and angiogenesis. Recent investigations indicate that
constitutive activation of the PI3K pathway promotes
resistance to estrogen receptor and human epidermal growth
factor receptor (HER)2 directed therapy for breast cancer
patients [1,2]. The major mechanism for abnormal PI3K
activation in cancer is thought to be somatic mutation in the
genes that encode positive and negative effectors of this
pathway. These insights suggest that many breast cancers
exhibit a ‘genetic dependency’ on PI3K pathway mutations
that can be exploited for therapeutic gain. For example,
abnormal PI3K activation in breast cancer can occur though
amplification of the HER2 gene, the gene product of which is
effectively targeted with the monoclonal antibody
trastuzumab [3]. In addition, loss of expression of PTEN, a
powerful negative regulator of PI3K signaling, or functional
loss of PTEN due to PTEN gene mutations occurs in up to
50% of breast tumors and results in constitutive PI3K
pathway signaling [4,5]. Loss of PTEN expression produces
resistance to breast cancer endocrine therapy and
trastuzumab treatment, and is a predictor of poor prognosis
[1,2,5]. More recently, activating mutations in the PIK3CA
gene, which encodes the PI3K p110α catalytic subunit, were
found to occur in about 20–40% of breast tumors [6-9].
Interestingly, one study involving a large cohort of breast
tumor samples [9] reported that PIK3CA gene mutations are
mutually exclusive with PTEN gene loss, and that PIK3CA
mutations correlate with HER2 expression and estrogen
receptor positive status in breast tumors, although these
correlations were not seen in other studies involving smaller
samples sizes [7,8]. The RPS6KB1 gene, which encodes the
mammalian target of rapamycin (mTOR) effector P70 S6
protein kinase (S6K), is amplified in approximately 10% of
breast cancers [10,11]. RPS6KB1 gene amplification
correlates with HER2 overexpression in breast tumors,
possibly due to coamplification of RPS6KB1 with  HER2
(both genes reside on 17q).
Collectively these observations suggest that genomic
alterations leading to constitutive activation of the PI3K
pathway exist in the majority of breast cancers. However,
considerably more molecular epidemiologic work needs to be
performed if we are to appreciate the clinical implications of
these gene mutations/amplifications and how they relate to
each other in large data sets.
Potential therapeutic interventions
Derivatives of rapamycin, a specific inhibitor of the PI3K
pathway target mTOR, are currently under clinical trial
development for breast cancer treatment. Although these
trials have only recently begun, early results from a phase II
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trial with the rapamycin analog CCI-779 in a cohort of
patients with advanced disease [12] demonstrated
objective responses. Interestingly, patients responding to
treatment had tumors with HER2 overexpression and/or
loss of PTEN expression. Alternative small molecule
inhibitors are also under investigation. For example, when
the antitumor effects of celecoxib did not appear to be
entirely due to its function as a cyclo-oygenase-2 inhibitor,
this agent was found to interdict the PI3K pathway by
inhibiting phosphoinositide-dependent protein kinase
(PDK)-1 [13]. PDK-1 is a direct target of PI3K activity that
regulates the activity of downstream kinases, including Akt,
mTOR and S6K. Because PDK-1 is a more proximal
mediator of PI3K signals than is mTOR, PDK-1 inhibitors
target a larger portion of the PI3K pathway and potentially
offer a more effective treatment. However, celecoxib is a
weak PDK-1 inhibitor, and effective inhibition in patients
would require concentrations that are difficult to achieve in
vivo. Recently, two celecoxib derivatives, namely OSU-
03012 and OSU-03013, were shown to be potent PDK-1
inhibitors in vitro [14], and the properties of these agents
are explored by Kucab and coworkers in this issue of Breast
Cancer Research [15].
PDK-1 inhibitors attenuate signaling, cell
proliferation and cell survival in breast cancer
cells
Kucab and coworkers [15] tested the ability of OSU-03012
and OSU-03013 to attenuate PDK-1 dependent signal trans-
duction and cell proliferation/survival in HER2 overexpressing
(although not HER2 gene amplified) breast cancer cell lines.
They reported that both analogs effectively downregulated
PI3K/PDK-1 dependent signaling at low micromolar concen-
trations, consistent with the effect of the drugs as selective
PDK-1 inhibitors. Both compounds inhibited the phosphory-
lation of Akt and one of its substrates, namely glycogen
synthase kinase-3, as well as the mTOR substrate 4E binding
protein 1. These findings confirm that these analogs have the
ability to inhibit a wider range of PI3K pathway components
than do rapamycin derivatives. Breast cancer cell lines
exposed to OSU-03012 and OSU-03013 underwent cell
death and exhibited reduced rates of cellular proliferation,
although the specific effects with regard to each of these
processes were not entirely separable because of the
experimental design. The effects of OSU-03012 and
OSU-03013 as selective PDK-1 inhibitors must be
interpreted cautiously, however, because extensive
pharmacologic profiles for these drugs against a panel of
signaling enzymes has not been reported. Kucab and
coworkers performed experiments suggesting that one of the
celecoxib analogues, OSU-03012, exhibits greater specificity
for PDK-1, or at least the PI3K arm of the HER2-activated
signaling cascade, than does OSU-03013. The former may
therefore serve as an attractive lead compound for studies
examining the effect of PDK-1 inhibition in preclinical breast
cancer modeling studies.
Finally, the authors examined a large cohort of breast tumor
samples in an effort to correlate phosphorylated Akt (P-Akt)
staining with clinicopathologic variables and HER2 expression.
The authors found that P-Akt staining did correlate with
higher levels of HER2 expression, but they were unable to
correlate P-Akt with overall survival. The failure of P-Akt
staining to serve as an adequate prognostic marker in this
study is not clear, but this might have resulted from the
absence of standardized treatment in the sample cohort.
Previous studies reporting P-Akt staining as a poor
prognosismticker involved cohorts of patients receiving
standardized treatment regimens [16-18], suggesting that the
value of P-Akt staining as a prognostic marker may be
treatment specific. Moreover, P-Akt staining is a continuous
biologic variable, and so quantifying P-Akt staining as
‘absent’, ‘weak’, ‘moderate’, or ‘strong’ introduces variability
into data interpretation. We suspect that there will not be an
antibody-based test to provide a reliable shortcut to identify
tumors that are responsive to PI3K inhibition, and direct
detection of the numerous somatic mutations that drive the
PI3K pathway will be necessary.
What is the potential of PDK-1 inhibitors in
breast cancer treatment?
Kucab and coworkers [15] mention that preliminary in vivo
studies indicate that OSU-03012 has significant bioavailability
and treatment produces low overt toxicity. In addition, recent
preclinical experiments indicated that OSU-03012 treatment
may combat imatinib resistance in models of chronic
myelogenous leukemia [19] and suggested a use in the
treatment of chronic lymphocytic leukemia [20]. OSU-03012
should certainly be pursued in breast cancer treatment. As
these studies progress, two important considerations must be
taken into account.
First, the determinants of responsiveness of breast cancer
cells to PDK-1 inhibitors must be identified. Based on
measurements of the sensitivity of breast cancer cell lines to
rapamycin analogs, the loss of PTEN expression or the
presence of P-Akt or phosphorylated S6K predicts
sensitivity to this class of agent [21]. Interestingly,
rapamycin-sensitive breast cancer cell lines contain one or
more aberrations that are capable of directly activating
components of the PI3K pathway, including PTEN loss
[21,22], HER2 overexpression, or PIK3CA gene mutations
[7,9]. Both breast cancer cell lines used by Kucab and
coworkers to test the efficacy of PDK-1 inhibitors contain
activating  PIK3CA gene mutations in addition to HER2
overexpression. Therefore, it is unclear whether HER2
overexpression, genetic aberrations within the PI3K pathway,
or a combination of these or other factors are predictors of
response to PDK-1 inhibitors. These observations
underscore the need to identify determinants of breast
cancer sensitivity to inhibitors of PDK-1 through the rigorous
analysis of multiple markers, which would include PTEN
mutation status, HER2 gene amplification, PI3KCA214
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mutational status, and levels of P-Akt and phosphorylated
S6K (or gene amplification tests for the relevant genes).
Second, studies designed to test the efficacy of PDK-1
inhibitors either alone or in drug combinations in breast
cancer models should be performed in parallel with those
using rapamycin derivatives. This will be necessary to
compare drug sensitivity profiles, especially in rapamycin-
resistant breast cancer models [21], so that the potential
application of PDK-1 inhibitors may be defined. Even
combinations of the two agents may be justified, depending
on the nature of the gene mutation/amplification profile.
Conclusion
Inhibitors of components of the PI3K pathway may provide
breast cancer patients with significant therapeutic benefit.
Currently, mammalian target of rapamycin inhibitors are being
used in clinical trials, and inhibitors to PDK-1 show promise in
preclinical development. The central challenge for drug
development is to develop predictive biomarkers that
accurately identify patients who are likely to benefit from PI3K
pathway inhibitors. To do so, it will be imperative to analyze
various components of the PI3K pathway and factors that may
modify PI3K signaling in future preclinical modeling studies and
current clinical trials. The relationships between these markers
and cellular response or patient outcome with specific
treatment regimens must be codified in order to develop
appropriate individualized therapeutic recommendations.
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